• Obesity Neural Systems Expert Grill Presents Stetson Lecture
    September 6, 2018
    Harvey J. Grill, Ph.D., presented the Annual Stetson Lecture in Technological Advances in Medicine on Friday, September 14, 2018 in the UVM Davis Center’s Silver Maple Ballroom. Grill, a professor of behavioral neuroscience at the University of Pennsylvania and director of the Obesity Unit at the Institute of Diabetes, Obesity and Metabolism, discussed “Treating the Hyperphagia Driving Obesity: Neural Mechanisms of Feeding Inhibition.”
  • Jensen Co-Authors Global Criteria for Diagnosing Malnutrition
    September 5, 2018
    Although malnutrition is a serious concern associated with adverse outcomes and cost, no single existing approach to malnutrition diagnosis has achieved broad global acceptance. Now, thanks to more than two years’ work by members of the Global Leadership Initiative on Malnutrition (GLIM) working group, a consensus report, which outlines five criteria for malnutrition, has just been published in the latest issue of both the Journal of Parenteral and Enteral Nutrition and Clinical Nutrition.
  • LaMantia Invested as Inaugural Holly and Bob Miller Chair in Memory and Aging
    August 21, 2018
    More than 150 people gathered for a formal investiture ceremony honoring the University of Vermont’s newest endowed faculty members and recognizing the donors who made the positions possible on August 21, 2018 at the UVM Alumni House. Michael LaMantia, M.D., M.P.H., was invested as the inaugural Holly and Bob Miller Chair in Memory and Aging and Rosemary Dale, Ed.D., A.P.R.N., was invested as the first Holly and Bob Miller Professor in Nursing Leadership.
  • Teaching Academy Announces 16 New Members
    August 20, 2018
    Kathryn Huggett, Ph.D., director of the Teaching Academy at the Larner College of Medicine at the University of Vermont, has announced the names of 16 new members of the Teaching Academy.
  • Vaccine Testing Center a Site for New NIH Live, Attenuated Zika Vaccine Trial
    August 16, 2018
    Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, Md., and at the Vaccine Testing Center at the Larner College of Medicine at the University of Vermont in Burlington.